NUVB
Nuvation Bio Inc
NYSE: NUVB · HEALTHCARE · BIOTECHNOLOGY
$4.76
-6.77% today
Updated 2026-06-05
Market cap
$1.66B
P/E ratio
—
P/S ratio
11.64x
EPS (TTM)
$-0.43
Dividend yield
—
52W range
$2 – $10
Volume
4.0M
WallStSmart proprietary scores
28
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B7.8
Quality
B+2.5
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$12.33
+159.03%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy7 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $5.02M — positive
+ Revenue growth 2,599.00% QoQ
+ Debt/equity 0.03x — low leverage
Risks
- Thin margins at -102.10%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $7.87M | $62.90M | $143.05M |
| Net income | $-104.20M | $-75.80M | $-567.94M | $-204.63M | $5.40M |
| EPS | — | — | — | — | $-0.43 |
| Free cash flow | $-96.48M | $-68.07M | $-130.57M | $-173.78M | $5.02M |
| Profit margin | — | — | -7,213.76% | -325.31% | -102.10% |
Peer comparison
Smart narrative
Nuvation Bio Inc trades at $4.76. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. TTM revenue stands at $143.05M. with profit margins at -102.10%.
Frequently asked questions
What is Nuvation Bio Inc's stock price?
Nuvation Bio Inc (NUVB) trades at $4.76, on a P/S of 11.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Nuvation Bio Inc overvalued?
Nuvation Bio Inc carries a Smart Value Score of 28/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Nuvation Bio Inc (NUVB)?
The 12-month analyst consensus target is $12.33, about 159.0% above the current $4.76. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Nuvation Bio Inc's revenue?
Nuvation Bio Inc's trailing twelve-month revenue is $143.05M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio11.64x
ROE-45.69%
Beta1.52
50D MA$4.62
200D MA$5.17
Shares out0.35B
Float0.24B
Short ratio—
Avg volume4.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—